Q2 Earnings Fury: Graphite India & Epigral Crash, Krsnaa Diagnostics Skyrockets! See the Shocking Numbers!
Overview
Graphite India and Epigral shares fell sharply on Monday following their Q2 earnings reports. Graphite India's net profit dropped 60.5% to Rs 77 crore due to lower electrode prices, while Epigral reported a 37% year-on-year decline in net profit to Rs 51.2 crore with a fall in revenue. In contrast, Krsnaa Diagnostics saw its shares rise by 8% after announcing a 22% increase in net profit to Rs 23.94 crore for the September quarter.
Stocks Mentioned
Graphite India Limited and Epigral Limited experienced significant stock price declines on Monday after releasing their quarterly financial results, while Krsnaa Diagnostics Limited saw its stock surge.
Graphite India reported a 60.5% year-on-year drop in consolidated net profit for the quarter ended September 30, 2025, settling at Rs 77 crore, down from Rs 195 crore in the previous year. This profit reduction was primarily attributed to falling electrode prices and weaker operating margins. Consequently, its shares on the NSE closed 7.23% lower at Rs 535.50.
Epigral, a chemical manufacturer, also posted disappointing results, with net profit decreasing by 37% year-on-year to Rs 51.2 crore from Rs 81.3 crore. Its revenue from operations saw a 6.2% dip, falling to Rs 587.3 crore from Rs 626 crore in the same period last year. The company's shares consequently closed 7.65% down at Rs 1,522.
Conversely, Krsnaa Diagnostics shares advanced 8% to end at Rs 781.50 on the NSE. The company announced a healthy 22% rise in net profit for the September quarter, reaching Rs 23.94 crore. Analyst sentiment appears positive for Krsnaa Diagnostics, with an average "Buy" rating from three analysts and a median price target of Rs 1,127. Trading volume for Krsnaa Diagnostics was exceptionally high, with approximately 5.66 lakh shares changing hands, far exceeding its 30-day average. Year-to-date, Krsnaa Diagnostics stock has declined by 7.5%.
Impact: This news directly impacts the share prices of Graphite India Limited, Epigral Limited, and Krsnaa Diagnostics Limited, and could influence investor sentiment towards the industrial goods, chemicals, and healthcare/diagnostics sectors in India. The contrasting results highlight sector-specific challenges and opportunities.
Rating: 7/10
